| Early primary tumor size reduction is an independent predictor of improved ... - UroToday |
|
|
UroToday In metastatic renal cell carcinoma (mRCC) patients treated with targeted agents and their primary tumor (PT) in situ, early PT decrease in size correlates with improved overall PT response, but the effect on overall survival (OS) is unknown. |